Patents by Inventor Anthony Letai

Anthony Letai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11867687
    Abstract: The present invention provides methods of determining cell sensitivity to a therapeutic agent.
    Type: Grant
    Filed: July 2, 2020
    Date of Patent: January 9, 2024
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Jeremy Ryan, Anthony Letai
  • Patent number: 11867688
    Abstract: The present invention relates provides methods of predicting cell sensitivity to a test agent. In some embodiments, the cells are cultured in a culture medium having serum.
    Type: Grant
    Filed: July 27, 2020
    Date of Patent: January 9, 2024
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Anthony Letai, Patrick Bhola, Jeremy Ryan
  • Patent number: 11815508
    Abstract: The present invention provides methods of predicting cell sensitivity or resistance to a therapeutic agent.
    Type: Grant
    Filed: July 11, 2019
    Date of Patent: November 14, 2023
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Anthony Letai, Juan Jose Montero Boronat, Jeremy Ryan
  • Publication number: 20220163510
    Abstract: Aspects of the application provide methods and compositions for identifying and evaluating putative therapeutic agents for cancer by live cell imaging. Cell samples comprising cancerous cells that have been pre-treated with a test agent are contacted with a BH3 peptide, and samples are imaged by live cell imaging over a time interval. Methods of the application can be used to determine whether a patient is likely to benefit from treatment with a particular test agent.
    Type: Application
    Filed: February 26, 2020
    Publication date: May 26, 2022
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Anthony Letai, Patrick Bhola, Rebecca German
  • Patent number: 11225511
    Abstract: The invention provides peptides and the nucleic acid sequences that encode them. The invention further provides therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of apoptosis associated disorders.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: January 18, 2022
    Assignees: Howard Hughes Medical Institute, Dana-Farber Cancer Institute, Inc.
    Inventors: Stanley J. Korsmeyer, Anthony Letai
  • Patent number: 11215608
    Abstract: The present invention provides methods of determining cell sensitivity to a therapeutic agent.
    Type: Grant
    Filed: October 26, 2016
    Date of Patent: January 4, 2022
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventor: Anthony Letai
  • Publication number: 20210255167
    Abstract: The present invention provides methods of assessing toxicity using Dynamic BH3 profiling.
    Type: Application
    Filed: February 26, 2021
    Publication date: August 19, 2021
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Anthony Letai, Patrick Bhola, Jeremy Ryan
  • Publication number: 20210041419
    Abstract: The present invention relates provides methods of predicting cell sensitivity to a test agent. In some embodiments, the cells are cultured in a culture medium having serum.
    Type: Application
    Filed: July 27, 2020
    Publication date: February 11, 2021
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Anthony Letai, Patrick Bhola, Jeremy Ryan
  • Publication number: 20210018493
    Abstract: The present invention provides methods of determining cell sensitivity to a therapeutic agent.
    Type: Application
    Filed: July 2, 2020
    Publication date: January 21, 2021
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Jeremy Ryan, Anthony Letai
  • Patent number: 10761086
    Abstract: The present invention relates provides methods of predicting cell sensitivity to a test agent. In some embodiments, the cells are cultured in a culture medium having serum.
    Type: Grant
    Filed: April 27, 2016
    Date of Patent: September 1, 2020
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Anthony Letai, Patrick Bhola, Jeremy Ryan
  • Patent number: 10739333
    Abstract: In various aspects the invention provides methods of predicting sensitivity of a cancer cell to a therapeutic agent by contacting a test cell population BH3 domain peptide; measuring the amount of BH3 domain peptide induced mitochondrial outer membrane permeabilization in the test cell population; and comparing the amount of BH3 domain peptide induced mitochondrial outer membrane permeabilization in the test cell population to a control cell population that has not been contacted with the therapeutic agent. An increase in mitochondrial membrane permeabilization in the test cell population compared to the control cell population indicates the cell is sensitive to the therapeutic agent.
    Type: Grant
    Filed: September 18, 2014
    Date of Patent: August 11, 2020
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Jeremy Ryan, Anthony Letai
  • Publication number: 20200096499
    Abstract: The present invention provides methods of predicting cell sensitivity or resistance to a therapeutic agent.
    Type: Application
    Filed: July 11, 2019
    Publication date: March 26, 2020
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Anthony Letai, Juan Jose Montero Boronat, Jeremy Ryan
  • Patent number: 10393733
    Abstract: The present invention provides methods of predicting cell sensitivity or resistance to a therapeutic agent.
    Type: Grant
    Filed: September 19, 2013
    Date of Patent: August 27, 2019
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Anthony Letai, Juan Jose Montero Boronat, Jeremy Ryan
  • Publication number: 20180244740
    Abstract: The invention provides peptides and the nucleic acid sequences that encode them. The invention further provides therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of apoptosis associated disorders.
    Type: Application
    Filed: January 12, 2018
    Publication date: August 30, 2018
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Stanley J. Korsmeyer, Anthony Letai
  • Publication number: 20180128813
    Abstract: The present invention relates provides methods of predicting cell sensitivity to a test agent. In some embodiments, the cells are cultured in a culture medium having serum.
    Type: Application
    Filed: April 27, 2016
    Publication date: May 10, 2018
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Anthony Letai, Patrick Bhola, Jeremy Ryan
  • Publication number: 20180120297
    Abstract: The present invention provides methods of assessing toxicity using Dynamic BH3 profiling.
    Type: Application
    Filed: April 27, 2016
    Publication date: May 3, 2018
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Anthony Letai, Patrick Bhola, Jeremy Ryan
  • Patent number: 9902759
    Abstract: The invention provides peptides and the nucleic acid sequences that encode them. The invention further provides therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of apoptosis associated disorders.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: February 27, 2018
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Stanley J. Korsmeyer, Anthony Letai
  • Patent number: 9856303
    Abstract: The invention provides peptides and the nucleic acid sequences that encode them. The invention further provides therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of apoptosis associated disorders.
    Type: Grant
    Filed: December 13, 2010
    Date of Patent: January 2, 2018
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Stanley J. Korsmeyer, Anthony Letai
  • Publication number: 20170184567
    Abstract: The present invention provides methods of determining cell sensitivity to a therapeutic agent.
    Type: Application
    Filed: October 26, 2016
    Publication date: June 29, 2017
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventor: Anthony Letai
  • Publication number: 20170160267
    Abstract: The present invention provides methods of determining cell sensitivity to a therapeutic agent.
    Type: Application
    Filed: March 17, 2016
    Publication date: June 8, 2017
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventor: Anthony Letai